Patients with histologically or cytologically diagnosed colorectal cancer
Patients who are refractory or intolerant to standard treatment for unresectable advanced or recurrent colorectal cancer
Patients with measurable disease according to RECIST guideline ver 1.1
Patients who are able to take capsules orally
You may not be if
Patients with clinically relevant gastrointestinal, hepatic, musculoskeletal, respiratory, cerebral/cardiovascular, hematologic, oncologic, endocrine, immunologic, psychiatric, neurologic, or genitourinary diseases, or patients with conditions that are judged to threaten the safety of the participant or to affect the outcome of this clinical trial by the investigators
Patients with medical history of interstitial lung disease
Patients with chronic nausea, vomiting or diarrhea that may interfere with oral administration of the investigational drug
Patients with pulmonary embolism or central deep vein thrombosis.
Patients receiving treatment with strong CYP3A4 inhibitors or inducers.
Patients diagnosed and treated for osteoporosis or patients with a bone mineral density of less than T-score -2.5 at the time of screening
Patients with obvious bone metastases in the long bones, vertebrae, or other parts of the leg where gravity is applied
Clareo Health | Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer
